Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Down to earth Manual for A Modest Hyundai Ioniq Electric for Seniors - 2What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- 3Moon rush: These private spacecraft will attempt lunar landings in 2026
- 4What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- 5Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- The Best Web-based Courses for Ability Advancement
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- Flu cases are spiking earlier than usual. What you need to know.
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Seven deaths possibly linked to malfunctioning glucose monitors
- One killed, several injured in Iran missile barrage on southern, central Israel
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- How to Build a Yard That Helps Monarchs During Spring Migration
- Tremendous Spelunking: Cool Caverns All over the Planet
